How Does Kisqali Help Lower the Risk of Breast Cancer Recurrence?
Cancer treatments do not always stop once the surgical intervention has been performed in cases where breast cancer has been detected early. Some patients may require further treatments to decrease their chances of breast cancer recurrence. The Kisqali 600mg Tablet, containing ribociclib as the active ingredient, is a CDK4/6 inhibitor that can be combined with hormone therapy in the treatment of HR-positive, HER2-negative early breast cancer.
What Is Breast Cancer Recurrence?
Breast cancer recurrence can be defined as the reappearance of the disease following primary treatment. The disease may recur either in the same area or elsewhere in the body. Various factors that may cause recurrence include tumor characteristics, lymph nodes involved, the stage of the disease, hormones, and treatments.
How Does Kisqali Help Reduce Recurrence Risk?
The medicine works by inhibiting the action of two proteins called CDK4 and CDK6 that facilitate the progression of cancer cells into the cell cycle phase for dividing. The inhibition of these proteins will enable the tablet to prevent the proliferation and growth of hormone-receptor positive breast cancer cells. This may prove effective in decreasing the chances of cancer recurrence.
Who May Benefit From Breast Cancer Treatment?
The medicine is not recommended to all people suffering from early stage breast cancer. There are some cases of early breast cancer which are HR-positive, HER2-negative where there is a high probability of recurrence. Some of the factors that doctors take into consideration while prescribing the treatment are as follows:
- Staging of cancer
- Features of tumor
- Involvement of lymph nodes
- Status of hormone receptors
- HER2 status
- Past treatment
- General health
How Is The Tablet Used During The Treatment?
For some treatment programs of early breast cancer, the medicine is administered orally at a dose of 600 mg once per day for 21 days followed by 7 days of drug holidays to create one 28-day cycle. However, treatment period and hormonal therapy are different based on the personal treatment program of the patient.
What Are the Common Side Effects of The Medicine?
The tablet has side effects, and monitoring is very essential throughout its use. The common side effects include:
- Low white blood cells
- Nausea
- Fatigue
- Diarrhea
- Headaches
- Liver function test abnormalities
- Loss of hair
It can alter the electrical conduction system of the heart by causing prolongation of the QT interval. Therefore, ECG and electrolyte level measurements are sometimes recommended by physicians.
Conclusion
This drug may assist in lowering the possibility of breast cancer recurrence by providing an edge in lowering the likelihood of recurrence among some people with HR-positive and HER2-negative breast cancer that is at high risk of recurrence. Given that Buy Kisqali 600mg tablet online in breast cancer is a search term relating to treatment, the patients must seek advice from their oncologists on whether the drug is suitable for their treatment regimen.
FAQs
1. For how long are patients administered the tablet for early breast cancer?
It is determined according to the particular condition for which this medication is prescribed. For example, a course of therapy can be considered for early-stage cancer.
2. Is Kisqali a chemotherapy drug?
It has an active component called ribociclib, which is a CDK4/6 inhibitor and a targeted anticancer drug.